Pazopanib (GW786034)

DRUG10 trials

Sponsors

GlaxoSmithKline, Illinois CancerCare, P.C., Sandy Srinivas, National Cancer Institute (NCI)

Conditions

Bladder (Urothelial, Transitional Cell) CancerBladder (Urothelial, Transitional Cell) Cancer Metastatic or UnresectableBladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Bladder CancerBrain TumorCancerCarcinoma, Renal Cell

Phase 1

A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients

CompletedNCT00363194

GlaxoSmithKlineCarcinoma, Renal Cell

Start: 2006-09-21End: 2009-06-19Updated: 2017-11-17

A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors

CompletedNCT00678977

GlaxoSmithKlineLung Cancer, Non-Small Cell

Start: 2008-04-03End: 2011-06-30Updated: 2017-11-14

A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors

CompletedNCT00722293

GlaxoSmithKlineNeoplasms, Breast

Start: 2008-07-08End: 2014-02-25Updated: 2017-11-13

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

WithdrawnNCT01130623

National Cancer Institute (NCI)Brain Tumor, Neuroblastoma, Osteosarcoma +2

Start: 2010-05-10End: 2011-11-18Updated: 2017-07-02

Phase 2

Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

CompletedNCT00430781

GlaxoSmithKlineMetastatic Cervical Cancer, Neoplasms, Uterine Cervix

Start: 2006-11-30End: 2011-07-31Updated: 2015-05-08

Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer

TerminatedNCT00549328

GlaxoSmithKlineLung Cancer, Non-Small Cell

Start: 2008-02-29End: 2009-04-30Updated: 2014-11-19

Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors

CompletedNCT00561795

GlaxoSmithKlineCancer, Cervix Diseases, Epithelial Ovarian Cancer +4

Start: 2007-09-30End: 2008-04-30Updated: 2012-03-22

Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade

TerminatedNCT00945477

Illinois CancerCare, P.C.Prostate Cancer

Start: 2009-07-31End: 2012-10-31Updated: 2013-11-18

GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line

TerminatedNCT01049776

Illinois CancerCare, P.C.Non Small Cell Lung Cancer

Start: 2010-01-31Updated: 2014-09-19

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

CompletedNCT01108055

Sandy SrinivasBladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable +2

Start: 2010-04-30End: 2015-07-31Updated: 2017-06-09

Related Papers

Phase II study of pazopanib with weekly paclitaxel in refractory urothelial cancer.

Journal of Clinical Oncology2015-03-0111 citations

A phase II study of pazopanib (GW786034) in patients with stage IV non-small cell lung cancer that have failed at least two prior chemotherapy regimens.

Journal of Clinical Oncology2014-05-203 citations